보고서 요약(국문)

개요
전 세계 사마귀 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
사마귀는 인유두종바이러스(HPV)에 의해 발생하는 양성 피부 병변입니다. 크기가 작고, 융기되어 있으며, 표면이 거칠고, 양배추 모양을 하고 있는 경우가 많습니다. 사마귀는 신체의 어느 부위에도 발생할 수 있지만, 주로 손, 손가락, 손톱 주변에 나타납니다.
전 세계 사마귀 치료 시장은 최근 몇 년간 크게 성장했으며, 이러한 상승세는 지속될 것으로 예상됩니다. 면역요법과 냉동요법의 도입 증가(자가 치료를 위한 간편한 냉동요법 키트의 보급 확대)와 같은 여러 주요 트렌드의 영향으로 시장은 변화의 시기를 겪고 있습니다.

시장 동향: 성장 동력 및 제약 요인
장기 이식 건수 증가
장기 이식 건수가 증가함에 따라 사마귀 치료 시장도 성장할 것으로 예상됩니다. 장기 이식 수혜자는 면역력이 저하된 상태이므로 인유두종 바이러스(HPV)로 인한 일반 사마귀와 같은 피부 사마귀 발생 위험이 높습니다. 이식 후 피부 종양 발생 가능성은 면역력이 정상인 사람보다 훨씬 높습니다. 사마귀 유병률은 면역억제 기간이 길어질수록 증가하여 이식 후 4~5년 이상 경과한 환자에서는 50~90%에 달합니다.
사마귀 발생은 사용된 면역억제제와 이식 간 간격에도 영향을 받습니다. 또한, 일반 사마귀(verruca vulgaris)는 신장 이식 후 흔히 발생하는 합병증입니다. 2023년 바이시덩 출판 그룹에서 발표한 보고서에 따르면, 신장 이식을 받은 60명의 어린이와 청소년을 대상으로 한 연구에서 사마귀 발생률은 28%였으며, 신장 이식 후 시간이 지남에 따라 유병률이 증가하는 것으로 나타났습니다. 위에 언급된 요인들로 인해 시장은 예측 기간 동안 성장할 것으로 예상됩니다.
시장 동향: 제약 요인
일반 사마귀와 같은 눈에 띄는 피부 질환에 대한 사회적 낙인은 미용 및 사회적 편견을 야기하며, 이는 환자에게 불편함이나 자의식을 유발할 수 있습니다. 이러한 낙인은 때때로 질환에 대한 오해에서 비롯되며, 사람들이 치료를 받는 것을 꺼리게 만들 수 있습니다.
또한, 냉동 치료나 외과적 제거와 같은 치료로 인한 흉터나 피부 손상에 대한 우려도 특히 사마귀가 눈에 잘 띄는 부위에 있는 경우 치료를 꺼리게 하는 요인이 될 수 있습니다. 이러한 심리적, 미용적 요인과 고통스러운 치료 방법에 대한 불안감은 사람들이 일반 사마귀 치료를 받지 않도록 하여 예측 기간 동안 시장 성장을 저해할 수 있습니다.

시장 세분화 분석
전 세계 사마귀 치료 시장은 치료 유형, 연령대, 판매 채널 및 지역별로 세분화됩니다.
약물 치료 부문은 사마귀 치료 시장 점유율의 약 32.2%를 차지했습니다.
약물 치료 부문은 접근성, 편리성, 비침습적 특성으로 인해 전 세계 사마귀 치료 시장에서 54.2%의 시장 점유율을 차지하며 지배적인 위치를 차지할 것으로 예상됩니다. 특히 경증에서 중등도 사마귀 환자에게 인기가 높습니다. 살리실산 및 이미퀴모드와 같은 활성 성분을 함유한 국소 크림, 용액, 젤을 포함하는 약물 치료는 환자의 일상생활에 거의 영향을 미치지 않으면서 사마귀를 효과적으로 치료할 수 있는 방법을 제공합니다.
또한, 살리실산 용액은 사마귀에 얇은 막을 형성하여 각질 용해 작용을 하는 각질 용해제로 작용하기 때문에 사마귀 치료에 가장 일반적으로 사용되는 약물 치료법입니다. 살리실산 용액은 사마귀 표면의 과도한 각질을 화학적으로 제거하고 염증 반응을 유도합니다. 게다가 살리실산은 약국에서 처방전 없이도 쉽게 구할 수 있습니다. 이 용액은 사마귀 치료에 매우 효과적인 것으로 나타났습니다. 예를 들어, 미국 국립 의학 도서관의 2022년 보고서에 따르면 살리실산을 사용한 사람 100명 중 약 39명이 위약을 투여받은 사람들에 비해 사마귀가 완전히 사라진 것으로 나타났습니다. 따라서 우수한 효능과 효과 덕분에 이 분야는 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 37.4%를 차지했습니다.
북미는 HPV 감염 및 이와 관련된 암 발병률 증가, 사마귀에 대한 인식 제고, 그리고 신제품 출시 등으로 인해 예측 기간 동안 전체 시장 점유율의 약 37.4%를 차지할 것으로 예상됩니다.

예를 들어, 미국 질병통제예방센터(CDC)의 2023년 보고서에 따르면, 미국에서는 매년 약 46,711건의 새로운 암 사례가 인유두종바이러스(HPV)와 관련된 신체 부위에서 진단됩니다. 이 중 여성 환자는 25,689명, 남성 환자는 21,022명입니다.
또한, 이러한 암 사례 중 약 37,000건은 HPV 감염과 관련이 있습니다. 여성에게서 가장 흔한 HPV 관련 질환은 자궁경부암이며, 남성에게서는 혀뿌리와 편도선을 포함한 목구멍 뒤쪽 부위의 악성 종양인 구강인두암이 가장 흔합니다. 따라서 이러한 요인들로 인해 향후 예측 기간 동안 해당 부위의 발병률은 증가할 것으로 예상됩니다.

코로나19 영향 분석
코로나19 및 코로나19 백신 접종으로 인해 사마귀가 발생한 사례가 여러 건 보고되었습니다. 한 보고서에서는 COVID-19에 감염된 장기 이식 환자에게서 오랫동안 치료에 저항성을 보였던 사마귀가 사라진 사례를 구체적으로 언급하고 있습니다. COVID-19로 인한 환자의 저산소 상태가 사마귀 퇴행에 영향을 미쳤을 가능성이 있습니다. 또 다른 연구에서는 SARS-CoV-2 감염이 지연형 과민 반응을 유발하여 바이러스 제거를 시작했을 수 있다고 제안합니다. 이는 병변 내 MMR 및 BCG 백신, PPD, 트리코피톤 항원 주사를 이용한 난치성 사마귀 치료에서 관찰된 바와 같습니다.
세 번째 연구에서는 ChAdOx1S COVID-19 백신 접종 후 일반적인 바이러스성 사마귀가 사라진 사례를 보고하고 있습니다. 마지막으로, 한 보고서에 따르면 COVID-19 치료 중 사마귀가 퇴행한 사례가 두 건 확인되었습니다.

경쟁 환경
일반 사마귀 치료제 시장의 주요 글로벌 업체로는 Prestige Consumer Healthcare Inc., STADA Arzneimittel AG, Bausch Health Companies Inc., Pfizer Inc., Verrica Pharmaceuticals, GlaxoSmithKline plc, Taro pharmaceutical Industries Ltd., Orgenesis biotech company, Teva pharmaceutical industries Ltd., Novan Inc. 등이 있습니다.
주요 개발 사항
• 2023년 6월 14일, 차세대 임상시험 관리 서비스를 제공하는 기술 중심의 글로벌 CRO인 Vial은 캘리포니아주 샌디에이고에 본사를 둔 비상장 바이오제약 회사인 Nielsen BioSciences, Inc.(Nielsen)와 일반 사마귀 치료제 CANDIN의 안전성 및 효능 연구를 위한 파트너십을 체결했습니다. Nielsen은 세포 매개 면역 반응에 광범위하게 적용되는 생물학적 제품의 개발 및 상용화에 주력하고 있습니다.

• 2023년 4월 10일, 키노파마는 이와키 세이야쿠와 협력하여 인유두종바이러스(HPV) 감염으로 발생하는 피부 사마귀 치료 후보 물질에 대한 2상 임상 시험을 시작했습니다.
보고서 구매 이유:

• 치료 유형, 연령대, 판매 채널 및 지역별 전 세계 사마귀 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 사마귀 치료 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

전 세계 사마귀 치료 시장 보고서는 약 61개의 표, 57개의 그림, 195페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Common Warts Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Common warts, commonly known as verruca vulgaris, are benign skin growths that are caused by the human papillomavirus (HPV). They are often tiny, raised, rough, and cauliflower-like in appearance. Common warts can appear on any area of the body, although they are most usually found on the hands, fingers, and around the nails.
The global common warts treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such increasing adoption towards immunotherapy and cryotherapy due to its availability of easy-to-use cryotherapy kits for self-treatment.
Market Dynamics: Drivers and Restraints
The increasing number of organ transplant
The market for common warts treatment is expected to grow as the number of organ transplants increases. Owing to their immunocompromised state, organ transplant recipients are more susceptible to developing warts such as common warts caused by human papillomavirus (HPV). After transplantation, the chance of acquiring cutaneous tumors is substantially higher than in the immunocompetent population. The prevalence of warts increases with the duration of immunosuppression, reaching 50-90% in patients more than 4-5 years after transplantation.
The development of warts is also affected by the immunosuppressant used and the time interval between transplants. Furthermore, cutaneous common warts (verruca vulgaris) are a common complication following kidney transplantation. According to a report published in Baishideng Publishing Group in 2023, the incidence of warts was 28% in a study of 60 children and adolescents with KT, with increasing prevalence with time after kidney transplantation. As a result of the factors listed above, the market is expected to grow throughout the forecast period.
Market Dynamics: Restraint
Cosmetics and stigma concerns about common warts arise from the social stigma associated with visible skin disorders such as common warts, which may cause persons uncomfortable or self-conscious. This stigma is sometimes caused by misconceptions about the condition and might discourage people from seeking medical treatment.
Moreover, concerns about scars or skin damage from treatments like cryotherapy or surgical removal can also prevent people from seeking help, especially if the warts are in prominent areas. These psychological and cosmetic factors, along with anxiety about painful treatment methods, can prevent people from treating common warts thereby restraining the market over the forecast period.
Segment Analysis
The global common warts treatment market is segmented based on treament type, age group, sales channel and region.
The drug therapy segment accounted for approximately 32.2% of the common warts treatment market share
The drug therapy segment is expected to dominate the global common warts treatment market accounted for 54.2% market share, due to its accessibility, convenience, and non-invasive nature, which makes it a popular choice, particularly for mild to moderate cases. Drug therapies, which include topical creams, solutions, and gels containing active ingredients such as salicylic acid and Imiquimod, offer patients an effective way of treating common warts while causing little impact on their everyday lives.
Furthermore, salicyclic acid solutions is most commonly used drug therapy for common warts, as this solution forms a thin layer over the wart. It works as keratolytic therapy that works by chemically debriding the wart of excess keratin and inducing an inflammatory response. Moreover, it is readily available without prescription too in pharmacies. This solution has shown very effective for treating this warts. For instance, according to National Library of Medicine 2022 report study, states that about 39 out of 100 people who used salicylic acid no longer had any warts in compare to people that received placebo. Thus, due to better efficacy and effectiveness the segment is expected to dominate over the forecast period.
Geographical Penetration
North America accounted for approximately 37.4% of the market share in 2022
North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing number of prevalence of HPV and associated cancer with this HPV infection, growing awareness about the warts and launch of new products will drive this region further during the forecast period.
For instance, according to Centers for Disease Control and Prevention 2023 article, In the U.S., approximately 46,711 new cancer cases are diagnosed each year in areas of the body that are usually associated with human papillomavirus (HPV). There are 25,689 female cases and 21,022 male cases among these.
Moreover, HPV is responsible for around 37,000 of these cancer cases. Cervical cancer is the most common HPV-linked disease in women, whereas oropharyngeal cancers, which include malignancies in the throat's posterior region, including the base of the tongue and tonsils, are the most common in men. Thus, owing to above factors the region is expected to grow over the forecast period.
COVID-19 Impact Analysis
There have been multiple cases of COVID-19 and COVID-19 vaccinations causing warts. One report specifics the elimination of long-standing treatment-resistant warts in a transplant patient during COVID-19. The patient's hypoxic state as a result of COVID-19 may have an effect on wart regression. Another study proposes that SARS-CoV-2 infection may have initiated viral clearance by generating a delayed hypersensitivity reaction, as seen in the treatment of recalcitrant warts with intralesional MMR and BCG vaccine, PPD, and trichophyton antigens.
A third study reports the disappearance of common viral warts following the administration of the ChAdOx1S COVID-19 vaccination. Finally, two incidences of wart regression were identified during COVID-19 treatment, according to a report.
Competitive Landscape
The major global players in the common warts treatment market include Prestige Consumer Healthcare Inc., STADA Arzneimittel AG, Bausch Health Companies Inc., Pfizer Inc., Verrica Pharmaceuticals, GlaxoSmithKline plc, Taro pharmaceutical Industries Ltd., Orgenesis biotech company, Teva pharmaceutical industries Ltd., Novan Inc. and among others.
Key Developments
• On June 14, 2023, Vial, a worldwide technology-driven CRO that provides next-generation clinical trial administration services, has partnered up with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to investigate the safety and efficacy of CANDIN for the treatment of common warts. Nielsen focuses on the development and commercialization of biological products that have broad applications in cell-mediated immune responses.
• On April 10, 2023, KinoPharma started a Phase II clinical trial of a medication candidate to treat cutaneous warts, a human papillomavirus (HPV) infection, in collaboration with IWAKI SEIYAKU.
Why Purchase the Report?
• To visualize the global common warts treatment market segmentation based on treatment type, age group, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of common warts treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global common warts treatment market report would provide approximately 61 tables, 57 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Age Group
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing number of organ transplant
4.1.2. Restraints
4.1.2.1. Cosmetics and stigma concerns
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Salicylic Acid
7.2.2.2. Silver Nitrate
7.2.2.3. Glutaraldehyde
7.2.2.4. Bleomycin
7.2.2.5. Imiquimod
7.2.2.6. Aminolevulinic Acid
7.3. Cryotherapy
7.4. Laser Therapy
7.5. Surgical Removal
7.6. Immunotherapy
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatric*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adult
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. End User*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.2.1. Hospitals
9.2.2.2. Dermatology Clinics
9.2.2.3. Homecare Settings
9.3. Distribution Channel
9.3.1.1. Hospitals Pharmacies
9.3.1.2. Retail Pharmacies
9.3.1.3. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Prestige Consumer Healthcare Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. STADA Arzneimittel AG
12.3. Bausch Health Companies Inc.
12.4. Pfizer Inc.
12.5. Verrica Pharmaceuticals
12.6. GlaxoSmithKline plc
12.7. Taro pharmaceutical Industries Ltd.
12.8. Orgenesis biotech company
12.9. Teva pharmaceutical industries Ltd.
12.10. Novan Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Prestige Consumer Healthcare Inc., 4. Key Developments, STADA Arzneimittel AG, Bausch Health Companies Inc., Pfizer Inc., Verrica Pharmaceuticals, GlaxoSmithKline plc, Taro pharmaceutical Industries Ltd., Orgenesis biotech company, Teva pharmaceutical industries Ltd., Novan Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Common Warts Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Common Warts Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Common Warts Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Common Warts Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Common Warts Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Common Warts Treatment Market Value, By Age Group, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 9 Global Common Warts Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 11 Global Common Warts Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Common Warts Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 14 North America Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 15 North America Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 16 North America Common Warts Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 South America Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 19 South America Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 South America Common Warts Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 Europe Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 23 Europe Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 24 Europe Common Warts Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Common Warts Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Common Warts Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Common Warts Treatment Market Value, By Age Group, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Common Warts Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 32 Prestige Consumer Healthcare Inc.: Overview

Table 33 Prestige Consumer Healthcare Inc.: Product Portfolio

Table 34 Prestige Consumer Healthcare Inc.: Key Developments

Table 35 STADA Arzneimittel AG: Overview

Table 36 STADA Arzneimittel AG: Product Portfolio

Table 37 STADA Arzneimittel AG: Key Developments

Table 38 Bausch Health Companies Inc.: Overview

Table 39 Bausch Health Companies Inc.: Product Portfolio

Table 40 Bausch Health Companies Inc.: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Verrica Pharmaceuticals: Overview

Table 45 Verrica Pharmaceuticals: Product Portfolio

Table 46 Verrica Pharmaceuticals: Key Developments

Table 47 GlaxoSmithKline plc: Overview

Table 48 GlaxoSmithKline plc: Product Portfolio

Table 49 GlaxoSmithKline plc: Key Developments

Table 50 Taro pharmaceutical Industries Ltd.: Overview

Table 51 Taro pharmaceutical Industries Ltd.: Product Portfolio

Table 52 Taro pharmaceutical Industries Ltd.: Key Developments

Table 53 Orgenesis biotech company: Overview

Table 54 Orgenesis biotech company: Product Portfolio

Table 55 Orgenesis biotech company: Key Developments

Table 56 Teva pharmaceutical industries Ltd.: Overview

Table 57 Teva pharmaceutical industries Ltd.: Product Portfolio

Table 58 Teva pharmaceutical industries Ltd.: Key Developments

Table 59 Novan Inc.: Overview

Table 60 Novan Inc.: Product Portfolio

Table 61 Novan Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 4 Global Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 5 Global Common Warts Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Common Warts Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 7 Drug Therapy Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Cryotherapy Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Laser Therapy Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Surgical Removal Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Immunotherapy Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Common Warts Treatment Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 13 Pediatric Age Group in Global Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Adult Age Group in Global Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Global Common Warts Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 16 End User Sales Channel in Global Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Distribution Channel Sales Channel in Global Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Global Common Warts Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 19 North America Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Asia-Pacific Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Europe Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 South America Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Middle East and Africa Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 North America Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 North America Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 26 North America Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 27 North America Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 28 North America Common Warts Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 29 South America Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 South America Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 31 South America Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 32 South America Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 33 South America Common Warts Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 34 Europe Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 35 Europe Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 36 Europe Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 37 Europe Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 38 Europe Common Warts Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 39 Asia-Pacific Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 40 Asia-Pacific Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 41 Asia-Pacific Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 42 Asia-Pacific Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 43 Asia-Pacific Common Warts Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Middle East & Africa Common Warts Treatment Market Value, 2021-2030 (US$ Million)

Figure 45 Middle East & Africa Common Warts Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 46 Middle East & Africa Common Warts Treatment Market Share, By Age Group, 2022 & 2030 (%)

Figure 47 Middle East & Africa Common Warts Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 48 Prestige Consumer Healthcare Inc.: Financials

Figure 49 STADA Arzneimittel AG: Financials

Figure 50 Bausch Health Companies Inc.: Financials

Figure 51 Pfizer Inc.: Financials

Figure 52 Verrica Pharmaceuticals: Financials

Figure 53 GlaxoSmithKline plc: Financials

Figure 54 Taro pharmaceutical Industries Ltd.: Financials

Figure 55 Orgenesis biotech company: Financials

Figure 56 Teva pharmaceutical industries Ltd.: Financials

Figure 57 Novan Inc.: Financials

세계 사마귀 치료 시장 – 2023-2030

Global Common Warts Treatment Market -2023-2030